Teladoc Health's international president sells $60,948 in stock

Carlos Nueno, the President of International at Teladoc Health, Inc. (NYSE:TDOC), recently sold shares of the company, according to a filing with the Securities and Exchange Commission. On December 2 and 3, Nueno sold a total of 5,279 shares of common stock. The shares were sold at prices ranging from $11.23 to $11.927 per share, amounting to a total transaction value of $60,948. The transaction occurred as Teladoc, currently valued at $1.89 billion, shows signs of undervaluation according to InvestingPro analysis, despite facing profitability challenges.

Prior to these sales, Nueno exercised options to acquire 5,279 shares of common stock on November 29. Want deeper insights into Teladoc's insider trading patterns and financial health? InvestingPro subscribers get access to comprehensive analysis and 10 additional ProTips. These transactions were conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell shares. Following these transactions, Nueno no longer holds any shares directly.

In other recent news, Teladoc Health has launched an AI-driven Virtual Sitter solution, which aims to enhance patient safety and care in hospitals. The technology, featuring motion detection and pose estimation, allows for more efficient patient monitoring, potentially reducing the incidence of patient falls. This development is part of Teladoc Health's broader strategy to leverage technology to enhance healthcare experiences and outcomes.

On the financial front, Teladoc Health revealed third-quarter results for 2024, showing a 3% year-over-year decrease in consolidated revenue to $641 million. Despite the overall decrease, the Integrated Care segment experienced a 2.5% rise in revenue. However, the BetterHelp segment reported a 10% drop in revenue. The company's adjusted EBITDA for the quarter was $83.3 million.

Goldman Sachs initiated coverage on Teladoc Health, assigning a Buy rating to the company's stock. This outlook is based on a positive view for Teladoc's integrated care business, particularly its Chronic Care Segment, which is expected to drive membership and revenue growth. The firm also anticipates a turnaround in Teladoc's BetterHelp strategy, predicting growth after membership and utilization rates hit their lowest point by the end of 2025.

Looking ahead, Teladoc projects Integrated Care revenue to remain flat or rise up to 2.5% for the fourth quarter, with adjusted EBITDA margins projected between 12.25% and 13.75%. These are recent developments in the company's operations and financial performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.